Overview

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
1ST Biotherapeutics, Inc.